First-in-human Study of SAR443579 Infusion in Male and Female Children and Adult Participants With Relapsed or Refractory Acute Myeloid Leukemia (R/R AML), B-cell Acute Lymphoblastic Leukemia (B-ALL), High Risk-myelodysplasia (HR-MDS), or Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN)
Terminated · Phase 1, Phase 2 · NCT05086315
Conditions: Acute Lymphocytic Leukaemia, Acute Myeloid Leukaemia Refractory, Myelodysplastic Syndromes, Blastic Plasmacytoid Dendritic Cell Neoplasia
At a glance
- Research payments reported, 2025
- $1.7M
- U.S. investigators named
- 11
- Sites paid
- 10
- Planned or actual enrollment
- 101
About the trial
- Sponsor
- Sanofi
- Tested
- SAR443579 (drug)
- Dates
- Started 2021-12-08; completion 2025-06-13
- Results posted
- Yes
This is an open-label, multicenter, Phase 1/Phase 2, dose escalation and dose expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics and anti-leukemic activity of SAR443579 in various hematological malignancies.
From ClinicalTrials.gov, last updated 2026-07-06. Full record, eligibility and contacts (opens in a new tab)
Industry funding
Sanofi US Services Inc. reported $1.7M in research payments for this study in 2025 (71 payments).
Research payments usually go to hospitals, universities and research sites to run a study, not to the investigators personally. A payment is not evidence of wrongdoing.
U.S. investigators named on this study
- Anthony Stein, MD Hematology · Duarte, CA
- Martha L. Arellano, MD Hematology · Atlanta, GA
- David E. Avigan, M.D. Hematology & Oncology · Boston, MA
- Pinkal Desai, M.D. Hematology & Oncology · New York, NY
- Ioannis Mantzaris, M.D Legal Medicine (non-physician) · Bronx, NY
- Gregory K. Behbehani, M.D., PH.D. Hematology · Columbus, OH
- Jennifer N. Saultz, DO Internal Medicine · Portland, OR
- Sarah K. Tasian, MD Pediatric Hematology & Oncology · Philadelphia, PA
- Marina Konopleva, M.D. PHD Hematology & Oncology · Houston, TX
- Abhishek Maiti, MD Hematology & Oncology · Houston, TX
- Todd C. Cooper, DDS Oral & Maxillofacial Surgery · Kennewick, WA
Clinicians the company named as principal investigators in its Open Payments reports.
Sites paid to run it
- Children's Hospital of Philadelphia, PA $299,219
- Ut MD Anderson Cancer Center $262,367
- The Ohio State University Ccicmass Spectrometry and Proteomi Facility $254,753
- Seattle Children's Hospital, WA $208,939
- Weill Medical College of Cornell University Attn Joint Clinical Trials Office $207,732
- City of Hope National Medical Ctr $174,448
- Biomedical Research Alliance of New York LLC $165,085
- Emory University Hospital, GA $116,840
- Ohsu Hospital and Clinics, OR $22,680
Sources: CMS Open Payments research payments (program year 2025) and ClinicalTrials.gov, U.S. National Library of Medicine.